Product Information
TRI-ESTARYLLA TABLET is a generic product labeled by Xiromed LLC, priced at $0.1286 per EA under NDC 70700012185. Its NADAC has been published 370 times since May 29, 2019.
Manufacturer
Xiromed LLCNDC
70700012185
Classification
Generic
Dosage Form
KIT
Last Updated
6/17/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA090793On Market Since
9/1/2022
Price Statistics
The NADAC for TRI-ESTARYLLA TABLET has been published 370 times since May 29, 2019, and over the history we have for it it has declined 41.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1286 per EA |
|---|---|
| All-time high | $0.2207 (Jun 10, 2020) |
| All-time low | $0.1072 (Jul 17, 2024) |
| 52-week high | $0.1375 |
| 52-week low | $0.1286 |
| Median price | $0.1479 |
| Average price | $0.1578 |
| Largest weekly change | -19.9% (Jul 17, 2024) |
| Weeks tracked | 370 |
| Tracking since | May 29, 2019 |
Generic Alternatives
The matcher finds 8 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 8 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 18% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of TRI-ESTARYLLA TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRI-ESTARYLLA TABLET, manufactured by Xiromed LLC, is $0.1286 per EA (NDC 70700012185), effective Jun 24, 2026.
How has the price of TRI-ESTARYLLA TABLET changed over time?
Over the history we have for it, the NADAC for TRI-ESTARYLLA TABLET has declined 41.1%. It has been tracked across 370 weekly CMS publications since May 29, 2019.
What are the highest and lowest recorded NADAC prices for TRI-ESTARYLLA TABLET?
Since May 29, 2019, the NADAC for TRI-ESTARYLLA TABLET has ranged from a low of $0.1072 (Jul 17, 2024) to a high of $0.2207 (Jun 10, 2020), with a median of $0.1479 per EA.
Are there cheaper alternatives to TRI-ESTARYLLA TABLET?
Yes. 8 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, TRI-LO-ESTARYLLA TABLET, is $0.1049 per EA — about 18% below TRI-ESTARYLLA TABLET.
Who manufactures TRI-ESTARYLLA TABLET?
TRI-ESTARYLLA TABLET (NDC 70700012185) is labeled by Xiromed LLC, and CMS classifies it as a generic product.
Related Drugs
Same classification